Comprehensive Stock Comparison
Compare Kymera Therapeutics, Inc. (KYMR) vs Can-Fite BioPharma Ltd. (CANF) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CANF | -9.3% revenue growth vs KYMR's -16.7% |
| Quality / Margins | KYMR | -7.9% net margin vs CANF's -15.7% |
| Stability / Safety | CANF | Beta 0.36 vs KYMR's 1.31, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | KYMR | +191.4% vs CANF's +169.9% |
| Efficiency (ROA) | KYMR | -17.9% ROA vs CANF's -114.0%, ROIC -24.9% vs -448.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Kymera Therapeutics is a biopharmaceutical company developing targeted protein degraders — small molecules that harness the body's natural protein degradation system to eliminate disease-causing proteins. It generates revenue primarily through strategic partnerships and milestone payments from pharmaceutical collaborators — with potential future revenue from drug sales if clinical candidates succeed. The company's key advantage is its proprietary Pegasus platform for discovering novel protein degraders, which targets previously "undruggable" proteins and creates a pipeline of first-in-class therapies.
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
KYMR leads in 4 of 6 categories (Financial Metrics, Valuation Metrics). CANF leads in 1 (Risk & Volatility).
Financial Metrics (TTM)
KYMR is the larger business by revenue, generating $39M annually — 70.0x CANF's $560,000. KYMR is the more profitable business, keeping -7.9% of every revenue dollar as net income compared to CANF's -15.7%. On growth, CANF holds the edge at -36.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KYMRKymera Therapeuti… | CANFCan-Fite BioPharm… |
|---|---|---|
| RevenueTrailing 12 months | $39M | $560,000 |
| EBITDAEarnings before interest/tax | -$349M | -$9M |
| Net IncomeAfter-tax profit | -$311M | -$9M |
| Free Cash FlowCash after capex | -$234M | -$8M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -8.9% | -16.0% |
| Net MarginNet income ÷ Revenue | -7.9% | -15.7% |
| FCF MarginFCF ÷ Revenue | -6.0% | -14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -61.3% | -36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -11.4% | +36.4% |
Valuation Metrics
| Metric | KYMRKymera Therapeuti… | CANFCan-Fite BioPharm… |
|---|---|---|
| Market CapShares × price | $7.4B | $14.2B |
| Enterprise ValueMkt cap + debt − cash | $7.2B | $14.2B |
| Trailing P/EPrice ÷ TTM EPS | -24.76x | -4.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 189.51x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 4.88x | 6.34x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
KYMR delivers a -19.7% return on equity — every $100 of shareholder capital generates $-20 in annual profit, vs $-2 for CANF. CANF carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x. On the Piotroski fundamental quality scale (0–9), KYMR scores 4/9 vs CANF's 1/9, reflecting mixed financial health.
| Metric | KYMRKymera Therapeuti… | CANFCan-Fite BioPharm… |
|---|---|---|
| ROE (TTM)Return on equity | -19.7% | -2.1% |
| ROA (TTM)Return on assets | -17.9% | -114.0% |
| ROICReturn on invested capital | -24.9% | -4.5% |
| ROCEReturn on capital employed | -27.2% | -108.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.05x | 0.02x |
| Net DebtTotal debt minus cash | -$275M | -$5M |
| Cash & Equiv.Liquid assets | $357M | $5M |
| Total DebtShort + long-term debt | $82M | $104,000 |
| Interest CoverageEBIT ÷ Interest expense | -1403.21x | -580.71x |
Total Returns (with DRIP)
A $10,000 investment in KYMR five years ago would be worth $18,851 today (with dividends reinvested), compared to $2,351 for CANF. Over the past 12 months, KYMR leads with a +191.4% total return vs CANF's +169.9%. The 3-year compound annual growth rate (CAGR) favors KYMR at 42.8% vs CANF's 20.6% — a key indicator of consistent wealth creation.
| Metric | KYMRKymera Therapeuti… | CANFCan-Fite BioPharm… |
|---|---|---|
| YTD ReturnYear-to-date | +25.5% | +2059.1% |
| 1-Year ReturnPast 12 months | +191.4% | +169.9% |
| 3-Year ReturnCumulative with dividends | +191.1% | +75.3% |
| 5-Year ReturnCumulative with dividends | +88.5% | -76.5% |
| 10-Year ReturnCumulative with dividends | +174.7% | -98.5% |
| CAGR (3Y)Annualised 3-year return | +42.8% | +20.6% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than KYMR's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CANF currently trades 96.3% from its 52-week high vs KYMR's 88.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KYMRKymera Therapeuti… | CANFCan-Fite BioPharm… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 0.36x |
| 52-Week HighHighest price in past year | $103.00 | $4.93 |
| 52-Week LowLowest price in past year | $19.45 | $0.17 |
| % of 52W HighCurrent price vs 52-week peak | +88.7% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 77.9 | 68.6 |
| Avg Volume (50D)Average daily shares traded | 620K | 4.3M |
Analyst Outlook
Wall Street rates KYMR as "Buy" and CANF as "Buy". Consensus price targets imply 52.6% upside for CANF (target: $7) vs 28.4% for KYMR (target: $117).
| Metric | KYMRKymera Therapeuti… | CANFCan-Fite BioPharm… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $117.31 | $7.25 |
| # AnalystsCovering analysts | 26 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Kymera Therapeutics… (KYMR) | 100 | 227.36 | +127.4% |
| Can-Fite BioPharma … (CANF) | 100 | 20.34 | -79.7% |
Kymera Therapeutics… (KYMR) returned +89% over 5 years vs Can-Fite BioPharma … (CANF)'s -76%. A $10,000 investment in KYMR 5 years ago would be worth $18,851 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kymera Therapeutics… (KYMR) | $0.00 | $39M | — |
| Can-Fite BioPharma … (CANF) | $169500.00 | $674000.00 | +297.6% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kymera Therapeutics… (KYMR) | -14.1% | -7.9% | +43.6% |
| Can-Fite BioPharma … (CANF) | -40.7% | -11.7% | +71.3% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kymera Therapeutics… (KYMR) | -0.48 | -3.69 | -668.8% |
| Can-Fite BioPharma … (CANF) | -90 | -1.08 | +98.8% |
Chart 5Free Cash Flow — 5 Years
Kymera Therapeutics, Inc. generated $-234M FCF in 2025 (-80% vs 2021). Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021).
KYMR vs CANF: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is KYMR or CANF a better buy right now?
Analysts rate Kymera Therapeutics, Inc. (KYMR) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KYMR or CANF?
Over the past 5 years, Kymera Therapeutics, Inc. (KYMR) delivered a total return of +88.5%, compared to -76.5% for Can-Fite BioPharma Ltd. (CANF). A $10,000 investment in KYMR five years ago would be worth approximately $19K today (assuming dividends reinvested). Over 10 years, the gap is even starker: KYMR returned +174.7% versus CANF's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KYMR or CANF?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus Kymera Therapeutics, Inc.'s 1.31β — meaning KYMR is approximately 264% more volatile than CANF relative to the S&P 500. On balance sheet safety, Can-Fite BioPharma Ltd. (CANF) carries a lower debt/equity ratio of 2% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — KYMR or CANF?
Kymera Therapeutics, Inc. (KYMR) is the more profitable company, earning -794.4% net margin versus -1169.1% for Can-Fite BioPharma Ltd. — meaning it keeps -794.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYMR leads at -891.3% versus -1206.2% for CANF. At the gross margin level — before operating expenses — KYMR leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — KYMR or CANF?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is KYMR or CANF better for a retirement portfolio?
For long-horizon retirement investors, Can-Fite BioPharma Ltd. (CANF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.36)). Both have compounded well over 10 years (CANF: -98.5%, KYMR: +174.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between KYMR and CANF?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.